{"slideshow_credits": null, "snippet": "A proposal to ease testing requirements is seductive but raises concerns about safety.", "abstract": "Editorial contends Food And Drug Administration proposal that will lower bar for approving drugs to treat people at earliest stages of Alzheimer's disease raises troubling questions; calls on independent analysts to assess proposal and to determine whether FDA should demand very high level of proof of safety and effectiveness before exposing still-healthy people to possible harm.", "section_name": "Opinion", "print_page": "20", "document_type": "article", "byline": {"person": [], "organization": "THE EDITORIAL BOARD", "original": "By THE EDITORIAL BOARD", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/03/18/opinion/drugs-for-early-stage-alzheimers.html", "lead_paragraph": "A proposal to ease testing requirements is seductive but raises concerns about safety.", "headline": {"seo": "Drugs for Early-Stage Alzheimer&#8217;s", "main": "Drugs for Early-Stage Alzheimer\u2019s", "print_headline": "Drugs for Early-Stage Alzheimer\u2019s", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "514717c9fdc5926e7700086c", "word_count": "514", "multimedia": [], "pub_date": "2013-03-18T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Alzheimer's Disease", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Editorials", "name": "subject", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}